Datapoint: Dupixent Scores First-in-Class EoE Nod

Sanofi and Regeneron’s Dupixent last week became the first drug approved to treat eosinophilic esophagitis (EoE), a rare, progressive disease that causes severe inflammation of the esophagus. The FDA’s decision came more than two months before Dupixent’s original priority review date. The interleukin inhibitor was first approved in 2017, as a treatment for atopic dermatitis. For the treatment of atopic dermatitis, Dupixent holds covered or better status for 89% of all insured lives under the pharmacy benefit. 39% of insured lives have preferred access to Dupixent, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 5/23/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today